1Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patient with chronic hepatitis B[ J]. Clin Infect Dis,2003,36(915 ) :687-696.
4Nafa S, Ahmed S, Tavan D, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B[ J]. Hepatology, 2000,32 : 1078-1088.
2Suzuki F, Tsubota A, Arase Y, et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology, 2003,46 : 182-189.
3Kobayashi S, Ide J, Sata M. Detection of YMDD motif mututions in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol, 2001,34: 584-586.
4Gaia S,Mariano A,Smedile A,et al.Four years of treatment with lamivudine:clinical and virology evaluations in HBe antigen-negative chronic hepatitis B[J].Aliment Phamacol Ther,2004,20(3):281-287.
5Lai CL,Dienstag J,Schiff E,et al.Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B[J].Clin Infect Dis,2003,36(15):687-696.
6Lai CL,Chien RN,Leung N,et al.A one-year trial of lamivudine for chronic hepatitis B[J].N Engl J Med,1998,339(2):61-68.
7Melegari M,Scaglion PP,Wands JR.Hepatitis B virus mutants associated with 3TC and Famciclovir administration are replication defective[J].Hepatology,1998,27(2):628-633.
8Chayama K,Suzuki Y,Kobayshi M,et al.Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy[J].Hepatology,1998,27(6):1711-1716.
